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Objectives: The aim of this study was to review, systematically and critically, evidence
used to derive estimates of cost-effectiveness of human immunodeficiency virus (HIV)
screening.
Methods: A systematic review was conducted. Searched were three main electronic
bibliographic databases from 1993 to 2008 using key words including HIV, mass
screening, HAART, economic evaluation, cost-effectiveness analysis, modeling. We
included studies of sexually transmitted HIV infection in both sexes, including studies
comparing diagnostic testing protocols and partner notification. Outcomes included were
cases of HIV infection detected, deterioration to the AIDS state, secondary transmission
of HIV, the quality-adjusted life-years/survival, costs, and cost-effectiveness of HIV
screening.
Results: Eighty-four papers were identified; ten of which were formal economic
evaluations, one cost study, three effectiveness studies, and three systematic reviews of
HIV prevention programs. The predominant assertion was that HIV screening is
cost-effective; methodological problems, such as the preponderance of static models
which are inappropriate for infectious diseases, varying perspectives from which the
studies were analyzed, and arbitrary threshold incremental cost-effectiveness ratio levels,
limited the validity of these findings, and their usefulness in informing health policy
decisions.
Conclusions: The majority of published economic evaluations are based on
inappropriate static models. This flaw renders the results of these studies as inconclusive
and the purported cost-effectiveness of HIV screening debatable. The results of this
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review could form a basis for consideration of further research and analysis by health
economists into the cost-effectiveness of HIV screening.
Keywords: Human Immunodeficiency Virus (HIV), Economic evaluation, Economic
modeling
Human immunodeficiency virus (HIV) infection has had an
unparalleled and pandemic impact since its discovery in the
early 1980s. It has demonstrably changed demographic pro-
files in the most affected geographical areas by markedly
reducing life expectancies, aggravating poverty, and ham-
pering economic growth by annihilating people in their most
productive years (3).
Globally, health systems have responded by financing
and providing screening services, following the recommen-
dations of economic evaluations which typically suggest HIV
screening is a cost-effective use of health resources.
The provision of valid information that can inform health
policy requires robust evidence about the cost-effectiveness
of the particular programs. Mathematical models such as de-
cision analyses and Markov models which predominate in
health economic evaluations (5) assume a constant force of
infection and treat individuals independently of each other
within their structure (2;5). These models are typically re-
ferred to as Static and are inappropriate for modeling the im-
pact of an HIV screening program. They cannot account for
the dynamics of transmission of the infection which is hinged
on its population prevalence per unit time, the duration of the
infectious period, the diversity of sexual behavior with its
potential for assortment and number of sexual partnerships
so formed within the population, as well as the presence of
concomitant sexually transmitted infections. These charac-
teristics can only be accommodated in transmission dynamic
models (23).
We undertook this review to appraise the methodologies
of economic studies of HIV screening carried out before and
beyond the advent of the highly active anti-retroviral therapy
(HAART) initiative. We assessed and critiqued the mathe-
matical models used in these studies, while expanding on the
appropriate model for analysis of HIV infection, to determine
the long-term cost-effectiveness of HIV screening. This re-
view is based on the study by Roberts et al. (22) who reviewed
and critiqued economic evaluations of Chlamydia screening
concluding that cost-effectiveness could not be determined
by these studies as they had profound methodological flaws;
principal among them being the inappropriateness of the
mathematical models on which the analyses were based.
MODELING AND HUMAN
IMMUNODEFICIENCY VIRUS SCREENING
HIV is predominantly transmitted during sexual inter-
course—it is mainly transmitted through heterosexual inter-
course but also bisexual and homosexual intercourse. Other
routes for transmission include vertically from an infected
mother to child, sharing needles between injecting drug
users, and by receiving infected blood products.
HIV infection, like Chlamydia, is often asymptomatic.
As a consequence, many people remain unaware of their
infection until they develop symptoms related to advanced
immunosuppression and AIDS. This delay in diagnosis not
only limits access to life-saving HAART, but there is also
evidence to suggest that people who are not aware of their
diagnosis are disproportionately responsible for the onward
transmission of HIV (15).
The natural history of HIV infection suggests that typi-
cally once a person is exposed to HIV and becomes infected,
approximately 1–6 weeks later between 50 and 80 percent of
people will feel unwell with perhaps one or more symptoms
of fever, headache, rash, or ulceration of the oropharynx,
general aches and pains, etc. Most people feel better within a
few weeks; hence they and their doctors think they had a bout
of the flu and miss an opportunity to screen for the disease.
However, this is one of the most infectious periods due to
high levels of the circulating virus in the bloodstream. As a
result of this and because they are unaware of their HIV sta-
tus, at-risk sexual behaviors continue and onward transmis-
sion occurs (15). The asymptomatic phase can vary in length
before the development of AIDS. Without treatment, the im-
mune system declines leaving people open to life-threatening
infections (combination of HIV and these infections is called
AIDS) and then death. People are again very infectious at
this stage due to high levels of the virus in the blood.
A fundamental understanding required for the construc-
tion of a mathematical model for any infectious disease is the
natural history of infection, because one of the main purposes
of the model is to depict the rate of transmission through a
defined community. Therefore, in the application of math-
ematical models to the economic evaluation of a screening
program for HIV, the most relevant characteristics are asso-
ciated with disease transmission. The costs and effectiveness
of the intervention, should be accounted for as far as possible
within the structure of the model before the potential impact
of the screening program can be analyzed (9;22).
METHODS
For ease of comparison this review was based on a similar
study by Roberts et al. (2006) (21). We searched three
main electronic bibliographic databases from 1993 to 2008
using keywords search strategy that included words such as
HIV or HIV infection, mass screening, HAART, economic
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Table 1. Criteria for Quality Assessment
• The research or study question should be explicit, implicit, or evident; its economic significance and social relevance should be
elucidated, and the perspective or standpoint of the study should be stated and justified
• The alternative health interventions being compared should be described vis-a`-vis their costs and outcomes, and the underlying principle
governing the ultimate choice of an intervention should be stated
• The type of economic study performed should be clearly stated and it should be appropriate to the stated objectives of the research
question within an appropriate time horizon
• All sources of effectiveness data should be explicit or implicit and methods of data analysis and extraction should be outlined
• The primary outcome measure of the study should be explicit, implicit or evident
• The quantities of resources used should be stated independently of the unit costs of these resources; the currency and/or currency
conversion rates as well as any inflation motivated price adjustments should be documented
• An appropriate and validated discount rate should be documented
• Incremental analysis should be performed when two or more alternatives are being compared
• The modeling type used in the study should be characterized, described, and should be appropriate for the study question
evaluation or cost-effectiveness analysis or cost benefit
analysis and modeling.
Inclusion Criteria
Participants. Individuals of both sexes at risk of ex-
posure to the human immunodeficiency virus.
Interventions. All available interventions for screen-
ing for HIV, including both nonselective and selective oppor-
tunistic and population-based screening programs.
Outcomes. The outcomes of interest were the cases
of HIV infection detected by screening; major outcomes
averted such as deterioration to the AIDS state and secondary
HIV transmission, the quality-adjusted life-years (QALYs)/
survival, costs, and cost-effectiveness of HIV screening.
Studies Reviewed. Formal economic evaluations;
such as cost-effectiveness analyses, cost-benefit analyses and
other studies which assess the effectiveness of HIV screen-
ing with a focus on assessment of costs likewise. Studies
reporting cost-effectiveness of HIV screening in pregnancy,
screening of blood products, and screening of injecting drug
users were excluded from this systematic review.
Selection of Papers for Review
The selection of papers for review was fashioned after a
similar methodology used by one of the co-authors (T.R.) of
this review and described in detail elsewhere (21).
The search was carried out in June 2008. The main inves-
tigator for the review (O.D.) followed the methods that have
been described in detail elsewhere (21). All stages of the re-
view were overseen by a second investigator (T.R.). The qual-
ity of the economic evaluations being reviewed was assessed
based on criteria derived from a synopsis of previously pub-
lished guidelines (Table 1) (21). Studies which failed to meet
more than two criteria were excluded, those which failed to
meet two criteria were reviewed and relevant deductions were
extracted, while those which failed to meet one or less than
one criterion were subjected to a full review and critique.
RESULTS
The search identified eighty-four papers (see Figure 1),
thirty-eight of which were considered potentially relevant.
Twenty-five papers were fully reviewed and those papers
which were categorized as economic evaluations or cost stud-
ies containing some useful information, classified as (C) but
not fully meeting the inclusion criteria were excluded. There
were ten formal economic evaluations, one cost study, three
effectiveness studies, and three systematic reviews of HIV
prevention programs. The models used in the different stud-
ies were also reviewed and documented.
Studies of Human Immunodeficiency Virus
Screening Programs
Fourteen studies, of the seventeen selected for the review,
were specifically designed with respect to HIV screening
programs. One of these fourteen studies also explored the
benefits of partner notification, as a consequence of screen-
ing, in limiting the spread of HIV. The general characteristics
of these studies are summarized in Table 2. Of these fourteen
studies, thirteen were model based, three were effectiveness
studies, and one was a cost study. Most of these studies used
rapid HIV antibody testing and found nonselective oppor-
tunistic screening programs to be cost-effective.
Static models predominated with only two studies
using transmission dynamic models in their analyses (4;27).
Vickerman et al. (27) evaluated the benefits of selective
population screening for HIV and other sexually transmitted
diseases and concluded that screening using rapid point
of care tests was more cost-effective than the prevailing
syndromic management of potentially infected female
commercial sex workers. Using a Bernoulli (stochastic
transmission) model, Bos et al. (4) analyzed the economic
impact of selective opportunistic screening of sexually
transmitted diseases (STD) clinic attendees and concluded
that screening was cost-effective presuming that behavioral
modification would be a consequence of detected HIV
sero-positivity.
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   Papers Screened 
            N = 84 
Papers excluded as being 
irrelevant to the systematic 
review. N = 46
      Potentially relevant studies 
           N = 38  
Papers further excluded based 
on lack of relevance.  N = 13 
                 Papers fully read 
          N = 25 
Papers excluded for not 
fulfilling the inclusion criteria. 
N = 8 
             Papers fully assessed 
         N = 17 
  Screening Studies 
             N = 14 
Comparisons of 
Screening Methods 
N = 7 
     Systematic Review 
                N = 3 
Screening and Partner 
Notification (Co-
heading)     N = 1
Figure 1. Algorithm depicting selection of economic evaluations of HIV screening.
Diagnostic Testing Studies
Seven studies addressed diagnostic testing protocols used for
HIV detection. The studies were categorized as those analyz-
ing the cost-effectiveness of enzyme linked immunosorbent
assay (ELISA) or enzyme immuno-assay (4;28;29), those
exclusively evaluating rapid testing protocols (18) and those
comparatively analyzing both protocols (4;6;17). Two of
these studies used transmission dynamic models to evalu-
ate the cost-effectiveness of rapid antibody testing protocols
as well as ELISA testing protocols (4;27), while the other
five studies were based on static models.
The studies unanimously concluded that HIV screening
by any means is cost-effective. The majority of the papers (57
percent) concluded that rapid antibody testing for HIV with
immediate patient notification is more cost-effective than al-
ternative tests which give results over a protracted period (ap-
proximately 2 weeks); and they result in a higher percentage
of patients being appropriately linked to care (6;17;18;27).
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Table 2. Summary of the Characteristics of the Economic Evaluations of HIV Screening in Chronological Order
First author; year
Target
population Model type Outcomes
Use of
HAART Main study conclusions
Fang; 2007 (8) M&F Static Life expectancy Yes Effectiveness Study. Screening should
be expanded to minimize delays in
diagnosis.
Holtgrave; 2007 (11) M&F Static HIV infections and
transmissions averted
Yes Screening is cost-effective. Targeted
counseling and testing performs
better than opt-out testing from an
effectiveness and public health
perspective.
Walensky; 2007 (28) M&F n/a QALY Yes Review of economic evaluations of
HIV screening. Screening is
cost-effective.
Paltiel; 2006 (17) M&F Static QALY, HIV cases detected,
transmissions averted
Yes Routine HIV screening is cost-effective;
except when the prevalence of
undetected infection is below 0.2%.
Vickerman; 2006 (27) F Dynamic Number of HIV cases averted n/a Screening is cost-effective. Rapid
Ng/Ct POC more cost-effective than
existing syndromic management.
Coco; 2005 (6) M&F Static QALY, secondary transmission
averted
Yes Expanded testing for primary HIV
infection may be cost-effective.
Paltiel; 2005 (18) M&F Static QALY Yes Routine voluntary HIV screening once
every 3 to 5 years is cost-effective;
except in settings of lowest
prevalence.
Sanders; 2005 (24) M&F Static QALY Yes Screening is cost-effective; even at
prevalence rates substantially less
than 1%.
Walensky; 2005(a) (29) M&F none HIV cases detected n/a
Walensky; 2005(b) (28) M&F Static QALY Yes Although screening is cost-effective;
limited funds allocated to client
notification and linkage to medical
care are a better value for money.
Walensky; 2005(c) (30) M&F Static QALY Yes Routine in-patient HIV screening is
cost-effective; even at undiagnosed
prevalence rates of 0.1%.
Ekwueme; 2003 (7) M&F Static HIV cases detected n/a
Bos; 2001 (4) M&F Dynamic QALY; secondary transmissions Yes Universal HIV screening of STD clinic
attendees is cost-effective.
Varghese; 1999 (26) M&F Static QALY; Yes Counseling and screening is cost
saving.




McCarthy; 1993 (16) M&F Static Life expectancy No Screening is cost-effective at prevalence
rates of 0.5% or more.
NSO, non-selective opportunistic screening; NSP, non-selective population screening; SO, selective opportunistic screening; SP, selective population
screening; HAART, highly active antiretroviral therapy; MOA, major outcome averted; F, female; M, male; QALY, quality-adjusted life-years; HIV, human
immunodeficiency virus infection; n/a, not applicable; STD, sexually transmitted diseases; Ng/Ct POC, Neisseria gonorrhoeae/Chlamydia trachomatis
point of care.
The general characteristics and summaries of details of these
studies are presented in Supplementary Table 1, which can be
viewed online at www.journals.cambridge.org/thc2010022.
Partner Notification Studies
One paper investigated the benefits of partner notification as
an adjunct to counseling and screening programs for HIV
prevention (26). The study used a decision model to simulate
the introduction of partner notification into an existing HIV
counseling and testing program and concluded that partner
notification piggy-backed onto a screening program is cost
saving both from the providers and societal perspectives. The
characteristics of this study are summarized in Supplemen-
tary Table 2.
Other Characteristics of the Studies
Overall the studies used long-term outcomes to measure ben-
efits of HIV screening. The majority of studies reported their
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results in generalizable outcome measures such as QALYs
or life-years gained (LYG). The exceptions are Fang et al. (8)
who reported their results in life expectancy, Holtgrave (11)
who reports in terms of infections and transmissions averted,
Walensky et al. (29), and Ekwueme et al. (7) who reported
their studies in terms of number of cases of HIV detected.
The two studies which were based on transmission dynamic
models were also reported with respect to secondary cases
averted. Coco (6) and Varghese et al. (26) considered the ben-
efits of HIV screening on secondary cases averted and HIV
transmission from infected index patients to their partners,
but based their analysis on static decision analysis models.
When evaluating HIV screening from the third party
payer’s perspective, Coco (6) reported in terms of cost per
case of primary HIV infection detected. Quality of life
data were derived from widely published studies of health
states and health utilities which were robust in their analyses
(7;13;20;25). Bos et al. (4) estimated the additional years of
life gained from screening as a function of HIV detection
during at least 3 years of the asymptomatic phase.
For many of the studies that reported incremental cost-
effectiveness ratios there was no discussion of a predeter-
mined acceptable threshold but their results were typically
interpreted as being cost-effective (11;17;27;28).
DISCUSSION
Within the limits of the electronic bibliographic databases
and journals searched, several economic studies which as-
sessed various aspects of HIV screening were identified and
subsequently reviewed. The unanimous conclusion of all
studies identified was that HIV screening was cost-effective.
The study that considered partner notification as an adjunct
to screening suggested that it was cost saving. Rapid HIV
antibody testing was found to be both clinically efficacious
as well as cost-effective.
Paying specific attention to the UK environment, the re-
view unearthed a dearth in economic studies of HIV screen-
ing programs. This finding was particularly disconcerting
considering the evidently rising incidence of HIV among
adults in the United Kingdom as reported by the Department
of Health in 2008. Three UK studies were identified on ante-
natal screening programs, but these studies are not critiqued
in the current review because the wider population effects
are not relevant and a static model is appropriate for such
evaluations (1;10;19).
HIV is an infectious disease that causes worldwide dev-
astation. The evidence presented in this study does not pur-
port to suggest that screening individuals and treating for this
disease is not good value for money. However, the findings
of this review raise questions on the validity of the reported
assertions made by the authors of some papers because many
of the assertions are underpinned by economic studies which
had methodological flaws. Principally, the models which
were predominantly used in the assessments were inappropri-
ate for modeling the dynamics of infectious diseases. Indeed
the methodological flaws, if absent might lead evidence to
show that the results supporting cost-effectiveness is actually
understated and that screening is even more cost-effective
than the available results suggest. Alternatively, model-based
economic evaluations that use an appropriate modeling ap-
proach may highlight with more precision, where the re-
sources should be targeted, to what groups, how often or
suggest other alternative but cost-effective policies.
Strengths and Limitations
The strengths of this study are that, to date and to our knowl-
edge, this is the only review of economic studies of HIV
screening to address the appropriateness and quality of the
models used in the studies. This is particularly important
vis-a`-vis the study by Roberts et al. (2006) on Chlamydia
screening as congruent concerns and matters surrounding
both areas of study can be underscored. A limitation of the
review is the limited scope of the search. There will exist
some databases that have not been searched and some stud-
ies not identified. However, our approach was pragmatic,
and the studies identified are recently published and in main
stream journals.
Comparison With Other Studies
Three other published systematic reviews in the area of HIV
were identified: two focused on HIV prevention inclusive of
screening (12;14) and one specifically reviewed screening
studies (28).
Hornberger et al. (14) reviewed and comprehensively
summarized studies of HIV prevention and management
from 1980 to 2005. Outcome measures which the authors
considered legitimate were the QALYs or LYGs. While the
review presented comprehensive literature-based evidence
on the cost-effectiveness of HIV screening, among other
HIV prevention strategies, it also highlighted methodolog-
ical flaws in economic studies reviewed such as varying
cost-effectiveness thresholds and questionable evidence on
effectiveness of the individual strategies. However, the au-
thors did not critique the approaches to modeling used in the
economic analyses reviewed and did not highlight this as a
limitation.
Walensky et al. (28) reviewed the methods and results
of economic studies of HIV screening in various clinical
settings in the United States. The review corroborated the
conclusions of existing studies, but neither the methodol-
ogy nor the strengths and limitations of their review were
discussed by the authors.
One of the earliest reviews of economic studies iden-
tified by the current study was by Holtgrave et al. (12).
The author reviewed economic studies of domestic HIV
screening programs from 1990 to 1995 across different pop-
ulations based on age, gender and level of risk; from in-
dividualistic, governmental and societal perspectives. The
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author did critique the modeling approaches used in some
of the studies and he buttressed the fact that economic stud-
ies should be based on clearly described and appropriate
models. Given the relative age of this review compared with
that of Walensky et al. (28) and Hornberger et al. (14), the
point made by Holtgrave in regard to the modeling is both
pertinent and advanced. However, it is also apparently ig-
nored or at best misunderstood by the subsequent published
studies.
The published reviews did support some of the find-
ings of this review, such as the variance in acceptable
threshold levels and the incomparability in measures of
outcome.
POLICY IMPLICATIONS
National and international HIV screening policies are today
informed by the results of erstwhile and current economic
evaluations of screening interventions. Given the widespread
devastation caused by this disease, such a finding is disap-
pointing to say the least. It is not the objective of this study
to suggest that current policies are not good value for money
or that the current strategies are misplaced. However, future
research must use the appropriate methods to support the vast
investments made to treat this disease and to ensure resources
are targeted appropriately.
Although the economic evaluations of HIV screening
included in this review have unequivocally lauded the cost-
effectiveness of screening, and such support may well be
correct, these assertions were predominantly informed by
static-model–based economic evaluations.
Thus, this review contends that, on the basis of the stud-
ies identified, the most efficient use of available resources to
combat HIV may not exist in current strategies. This review
presents a prominent example of situations where economic
analysts apply their standard toolkit or the most current or
fashionable approach to research questions which is simply
inappropriate. Such examples risk jeopardizing the impor-
tance of health economics and leaving champions of the
discipline poorly placed to object when economic evidence
is ignored in policy making. For these reasons, this review
principally maintains that health policy in the area of HIV
screening should be informed by studies carried out by multi-
disciplinary teams which include competence in economics,
modeling and the epidemiologists who understand the natu-
ral history of the disease. Good quality economic evidence
to decision makers is essential if the efficient and appropriate
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